The interim results on the first 415 patients randomized in the phase 3 ALPINE study showed a significantly better response for zanubrutinib compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds.
The interim results on the first 415 patients randomized in the phase 3 ALPINE study showed a significantly better response for zanubrutinib compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds and honorary consultant hematologist at Leeds Teaching Hospitals NHS Trust.
What do the interim results of the phase 3 ALPINE study of zanubritinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia show so far?
The ALPINE study compared zanubrutinib with ibrutinib, which are second-generation Bruton tyrosine kinase (BTK) inhibitors. The study is a large trial with 652 patients, but the interim results being presented at the European Hematology Association meeting are of the first 415 patients who were randomized.
The primary end point was overall response rate, which allowed for the trial to be reported earlier, and the follow-up is relatively short. The overall response was significantly better for zanubrutinib compared with ibrutinib at the 12-month time point, Hillmen explained. The outcome of the progression-free survival was also in favor of zanubrutinib, he added.
“As yet, not a significant difference in overall survival, although there is a trend to watch that space,” Hillmen said. “Also there’s a reduction, a significant reduction, in atrial fibrillation from 10% to 2.5% for zanu[brutinib].”
The study will be followed longer, the numbers will change, and there will be new adverse effects.
“There’s been a difference in hypertension, which is interesting, but that might be to do with the short follow-up,” Hillmen said. “So, I think we need further follow-up for the ALPINE study.”
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More